Zurcher Kantonalbank Zurich Cantonalbank Has $11.46 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 11.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,464 shares of the biotechnology company’s stock after acquiring an additional 3,341 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.07% of United Therapeutics worth $11,455,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics in the fourth quarter valued at about $25,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at about $33,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in United Therapeutics in the fourth quarter worth approximately $131,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 116,464 shares of company stock valued at $42,396,244. 11.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of analyst reports. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Performance

United Therapeutics stock opened at $307.09 on Thursday. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The firm has a market capitalization of $13.79 billion, a PE ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64. The business’s 50-day simple moving average is $351.85 and its 200-day simple moving average is $359.12.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period in the previous year, the business posted $4.36 EPS. Research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.